Your browser doesn't support javascript.
loading
Characterization and spatial distribution of the immune cell infiltrate in triple-negative breast cancer: a novel classification based on plasma cells and CD8+ T cells.
Gonzàlez-Farré, Mònica; Gibert, Joan; Santiago-Díaz, Pablo; Menéndez, Silvia; Monzonis, Xavier; Olivares, Francesc; Riera, Xènia; López, David; Torner, Ariadna; Casado, Beatriz; Bellosillo, Beatriz; Lloveras, Belén; Casadevall, David; Rovira, Ana; Servitja, Sònia; Albanell, Joan; Vázquez, Ivonne; Comerma, Laura.
Affiliation
  • Gonzàlez-Farré M; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain. Electronic address: mgonzalezfarre@psmar.cat.
  • Gibert J; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
  • Santiago-Díaz P; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
  • Menéndez S; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
  • Monzonis X; Department of Medical Oncology, Hospital del Mar, 08003 Barcelona, Spain.
  • Olivares F; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
  • Riera X; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
  • López D; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
  • Torner A; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
  • Casado B; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
  • Bellosillo B; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain; Department of Medicine and Life Sciences (MELIS), University Pompeu Fabra, Doctor Aiguader 88, 08003 Barcelona, Spain.
  • Lloveras B; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain; Department of Medicine and Life Sciences (MELIS), University Pompeu Fabra, Doctor Aiguader 88, 08003 Barcelona, Spain.
  • Casadevall D; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
  • Rovira A; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain; Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain.
  • Servitja S; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain; Department of Medical Oncology, Hospital del Mar, 08003 Barcelona, Spain.
  • Albanell J; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain; Department of Medical Oncology, Hospital del Mar, 08003 Barcelona, Spain; Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain; Department of Medicine and Life Sciences (M
  • Vázquez I; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
  • Comerma L; Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
Hum Pathol ; 139: 91-105, 2023 09.
Article in En | MEDLINE | ID: mdl-37517596
Stromal tumor-infiltrating lymphocytes (sTILs) are a robust prognostic and predictive biomarker in triple-negative breast carcinoma. However, the sTIL compartment comprises different cell populations. The aim of the study is to characterize the distribution of T cells (CD3+ and CD8+), B cells, and plasma cells and explore their association with outcome in the surgical specimen of 62 patients. Furthermore, programmed death ligand 1 expression and the presence of tertiary lymphoid structures (TLSs) are explored. Patients with higher sTILs achieve better progression-free survival (PFS) (P = .0013), and tumors have more plasma cells in the infiltrate. Specifically, higher counts of T cells (both CD3+ and CD8+) have better PFS (P = .002 and P = .0086, respectively) as it is observed in tumors with higher infiltration of CD8+ T cells in the tumor core (P = .035). Higher infiltration by B cells and plasma cells shows a positive tendency toward increased PFS (P = .06 and P = .058). Programmed death ligand 1 (SP142) is positive in 56% of tumors. Tumors with at least 1 TLS (42%) show higher CD8+ T cell infiltration in the tumor core and the sTIL value doubles compared to tumors devoid of TLSs [sTIL mean: 36 ± 11% and 18 ± 5% (CI [Confidence Interval]: 95%), respectively]. Our study demonstrates that the characterization of the immune cell infiltration is as relevant as its distribution. Moreover, the importance of considering different immune cell types for classification is emphasized. Therefore, a new classification of triple-negative breast carcinoma immune infiltration with CD8+ T cell and plasma cell densities in the tumor core and infiltrative margin is proposed.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Plasma Cells / Triple Negative Breast Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Hum Pathol Journal subject: PATOLOGIA Year: 2023 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Plasma Cells / Triple Negative Breast Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Hum Pathol Journal subject: PATOLOGIA Year: 2023 Type: Article